Bendamustine hydrochloride

Innomustine

普癌汰凍晶注射劑

100mg/vial

04. ANTINEOPLASTIC AGENTS; ;

04.01.CHEMOTHERAPY;;

04.01.01 ALKYLATING AGENTS

Alkylating Agent

(1)慢性淋巴球白血病 (2)曾接受至少一種化療之和緩性非何杰金氏淋巴瘤

D 已證實對人之胎兒有傷害，若是疾病對於孕婦有生命威脅或安全的藥品已無法治療的情況下，權衡利弊，仍可使用。

Unknown

Chronic lymphocytic leukemia(CLL):
IVF: 100 mg/m(2) IV infusion over 30 minutes on days 1 and 2; repeat every 28 days up to a maximum of 6 cycles
Non-Hodgkin's lymphoma(NHL):
IVF: 120 mg/m(2) IV infusion over 60 minutes on days 1 and 2 of a 21-day cycle, up to 8 cycles
Dosing: Adjustment for Toxicity
Treatment delay:
Hematologic toxicity ≥ grade 4: Delay treatment until resolves (ANC ≥1000/mm3, platelets ≥75,000/mm3)
Nonhematologic toxicity ≥ grade 2 (clinically significant): Delay treatment until resolves to ≤ grade 1
Dose modification CLL:
Hematologic toxicity ≥ grade 3: Reduce dose to 50 mg/m2 on days 1 and 2 of each treatment cycle. For recurrent hematologic toxicity (≥ grade 3), further reduce dose to 25 mg/m2 on days 1 and 2 of the treatment cycle.
Nonhematologic toxicity ≥ grade 3: Reduce dose to 50 mg/m2 on days 1 and 2 of each treatment cycle.
May cautiously re-escalate dose in subsequent cycles. Dose modification in NHL:
Hematologic toxicity grade 4: Reduce dose to 90 mg/m2 on days 1 and 2 of each treatment cycle. For recurrent hematologic toxicity (grade 4), further reduce dose to 60 mg/m2 on days 1 and 2 of each treatment cycle.
Nonhematologic toxicity ≥ grade 3: Reduce dose to 90 mg/m2 on days 1 and 2 of the treatment cycle with discretion. For recurrent toxicity ≥ grade 3, further reduce dose to 60 mg/m2 on days 1 and 2 of each treatment cycle.

Bone marrow Depression; Infection; Fatigue; Headache ; Nausea; Vomiting; Increased serum bilirubin;

已知對bendamustine 或 mannitol 過敏之病患；懷孕。

1.女性病患應在bendamustine治療期間以及於停藥後3個月內避免懷孕，接受bendamustine治療的男性病患也應於相同期間採取可靠的避孕措施。
2.需嚴密監測WBC、Platlet、Hb和Neutrophil。若於下一個週期的第1天尚未恢復至建議值，則需要延遲給藥。在下一個治療週期開始前，ANC 應≥1000/mm3, platelets 應≥75,000/mm3
3.本品常發生輸注反應，症狀包括發燒、發冷、皮疹和發癢。經歷第1或2級輸注反應的患者，應考慮在隨後的週期採取預防措施，包括給予antihistamines、antipyretics和corticosteroids，以防止發生嚴重反應。經歷第3或4級輸注反應的患者，則應考慮停藥。
4.曾有一些皮膚不良反應的案例被報導，包括皮疹、毒性皮膚不良反應和大皰性皮疹 (bullous exanthema)。發生皮膚不良反應的病患應被密集監測，如果發生嚴重皮膚不良反應或惡化，應當暫停或終止bendamustine之給藥。
5.配製及稀釋後儲存25℃可存放3.5小時；儲存2-8℃可存放2天。

建立者

104784

建立時間

2017-11-03 14:29:03

維護者

103617

維護時間

2022-05-10 09:18:34